Optionele productanalyse
Met uw toestemming gebruiken we privacyvriendelijke, beperkte analyses om te begrijpen welke onderzoeksroutes werken. We gebruiken geen advertentietrackers of sessieopnamen. U kunt deze keuze wijzigen in Voorkeuren. Lees het Privacybeleid.
Edwards Lifesciences Corporation's published Sell conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $49.3B | |
|---|---|---|
| P/E (forward) | 25.6x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $5.23B | $4.46B | $5.01B | $5.44B | $6.07B | +3.8% |
| Gross profit | $3.98B | $3.74B | $4.03B | $4.32B | $4.73B | +4.4% |
| Operating income | $1.69B | $1.50B | $1.31B | $1.38B | $1.26B | -7.0% |
| Net income | $1.50B | $1.52B | $1.40B | $4.17B | $1.07B | -8.1% |
| EPS (diluted) | $2.38 | $2.44 | $2.30 | $6.97 | $1.83 | -6.4% |
| EBITDA | $1.89B | $1.96B | $1.53B | $1.72B | $1.43B | -6.7% |
| R&D | $903.1M | $843.6M | $962.9M | $1.05B | $1.08B | +4.6% |
| SG&A | $1.49B | $1.36B | $1.58B | $1.79B | $2.09B | +8.7% |
Recent company headlines from major financial publishers.
Edwards maintains durable leadership in transcatheter heart valve replacement, supported by specialized clinician workflows and expanding center capacity under finalized NCD guidelines,. Revenue grows in line with consensus projections across FY2026 and FY2027 before fading toward terminal rates by FY2030. Operating margins expand from FY2026 through FY2030, supported by premium gross margins. Reinvestment moderates relative to NOPAT as capital expenditures scale down relative to revenue from FY2025 levels.
Accelerated implementation of finalized National Coverage Determination (NCD) policies opens substantial hospital cath lab capacity and center access, reigniting US TAVR procedural growth while early-stage asymptomatic indication expansions broaden the eligible patient population. Emerging transcatheter mitral and tricuspid therapies scale rapidly, lifting consolidated gross margin and operating margin. Normalizing capex intensity relative to revenue expands annual cash flows, driving accelerated share repurchases and compound earnings expansion.
| Ke ↓ / g → | 1.5% | 2.0% | 2.5% | 3.0% | 3.5% |
|---|---|---|---|---|---|
| 7.9% | $64.3 | $66.0 | $68.1 | $70.7 | $73.8 |
| 8.4% | $61.6 | $63.1 | $64.8 | $66.9 | $69.4 |
| 8.9% | $59.3 | $60.6 | $62.3 | $63.7 | $65.7 |
| 9.4% | $57.3 | $58.3 | $59.5 | $60.9 | $62.6 |
| 9.9% | $55.4 | $56.3 | $57.4 | $58.5 | $59.9 |
Upcoming earnings date and setup when available.
De rating die de gepubliceerde researcheditie van elke maand droeg. Een rating vergelijkt de koers op de analysedatum met de fair value; het is geen overzicht van of de inschatting juist bleek.
| Jaar | jan | feb | mrt | apr | mei | jun | jul | aug | sep | okt | nov | dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |
